Elevated quinolinic acid levels in cerebrospinal fluid in subacute sclerosing panencephalitis

Subacute sclerosing panencephalitis (SSPE) is a rare neurodegenerative disorder caused by a persistent infection with aberrant measles virus. Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2020-02, Vol.339, p.577088-577088, Article 577088
Main Authors: Inoue, Hirofumi, Matsushige, Takeshi, Ichiyama, Takashi, Okuno, Alato, Takikawa, Osamu, Tomonaga, Shozo, Anlar, Banu, Yüksel, Deniz, Otsuka, Yasushi, Kohno, Fumitaka, Hoshide, Madoka, Ohga, Shouichi, Hasegawa, Shunji
Format: Article
Language:English
Subjects:
Indoleamine-2, 3-dioxygenase
Kynurenine pathway
Quinolinic acid
Subacute sclerosing panencephalitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Subacute sclerosing panencephalitis (SSPE) is a rare neurodegenerative disorder caused by a persistent infection with aberrant measles virus. Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic effect for neurons. We measured serum IDO activity and cerebrospinal fluid (CSF) levels of QUIN. The CSF QUIN levels were significantly higher in SSPE patients than in controls, and increased according as neurological disability in a patient studied. Elevation of CSF QUIN and progression of SSPE indicate a pathological role of KP metabolism in the inflammatory neurodestruction. [Display omitted] •Quinolinic acid (QUIN) has an excitotoxic effect for neurons.•Cerebrospinal fluid QUIN was elevated in subacute sclerosing panencephalitis.•QUIN increased with a deterioration of neurological disability.•The QUIN accumulation might modify the inflammatory neurodestructive process.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2019.577088